ANGO — AngioDynamics, Inc. stock price, charts and financials

QT79AngioDynamics, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
15.19
+0.02+0.13%
ANGOQT79AngioDynamics, Inc.·NASDAQ
15.19+0.13%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.88Insider Own7.02%Shs Outstand41.33MPerf Week11.05%
Market Cap627.01MForward P/E-EPS next Y-0.04Insider Trans-0.80%Shs Float36.54MPerf Month15.89%
Enterprise Value599.01MPEG-EPS next Q-0.09Inst Own-Short Float3.60%Perf Quarter35.93%
Income-36.00MP/S1.96EPS this Y69.70%Inst Trans-Short Ratio3.41Perf Half Y46.43%
Sales320.00MP/B3.62EPS next Y83.13%ROA-13.75%Short Interest1.32MPerf YTD18.15%
Book/sh4.19P/C16.50EPS next 5Y-ROE-21.01%52W High15.43 -1.56%Perf Year71.22%
Cash/sh0.92P/FCF-EPS past 3/5Y-ROIC-20.75%52W Low8.37 81.46%Perf 3Y73.17%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-1.90% 1.92%Gross Margin54.62%Volatility3.52% 4.53%Perf 5Y-41.88%
Dividend TTM-EV/Sales1.87EPS Y/Y TTM-6.02%Oper. Margin-12.47%ATR (14)0.58Perf 10Y-8.17%
Dividend Ex-Date-Quick Ratio1.49Sales Y/Y TTM9.59%Profit Margin-11.48%RSI (14)69.60Recom2.55
Dividend Gr. 3/5Y-Current Ratio2.19EPS Q/Q-SMA2010.08%Beta0.30Target Price19.50
Payout0.00%Debt/Eq0.00Sales Q/Q8.75%SMA5018.08%Rel Volume1.86Prev Close15.17
Employees675LT Debt/Eq0.04EarningsOct 01SMA20028.62%Avg Volume416.62KPrice15.19
IPO DateJun 01, 2004Option/ShortYes / YesEPS/Sales Surpr.21.96% 7.93%Net Debt/EBITDA1.50Volume773,996Change0.13%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-15-26ReiteratedHC Wainwright & Co.Buy$14$19
Jul-15-26ReiteratedCanaccord GenuityBuy$18$20
Oct-03-25ReiteratedCanaccord GenuityBuy$17$18
Jul-16-25ReiteratedCanaccord GenuityBuy$12$17
Oct-04-24ReiteratedCanaccord GenuityBuy$12
Sep-20-24ReiteratedHC Wainwright & Co.Buy$14
Apr-05-24UpgradeOppenheimerPerformOutperform$12
Apr-17-23DowngradeRaymond JamesStrong BuyOutperform
Jan-06-23ReiteratedRaymond JamesStrong Buy$27$22
Jul-13-22ReiteratedRaymond JamesStrong Buy$27
Latest News
Jul-28-26
Jul-21-26
Jul-16-26
Jul-15-26
Jul-14-26
Jun-30-26
Jun-17-26
Jun-11-26
Company

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
5/31/2026
FY 2025
5/31/2025
FY 2024
5/31/2024
FY 2023
5/31/2023
FY 2022
5/31/2022
FY 2021
5/31/2021
FY 2020
5/31/2020
FY 2019
5/31/2019
Total Revenue320320292304339316291264359
Cost of Goods Sold Incl. D&A145145135149165150134114115
Gross Profit174175158155174166157150156
Selling, General and Administrative Excl. Other157157145144144134117117116
Research and Development292926323031363029
Other Operating Expense30292717151293917020
Operating Income-39-40-40-192-51-28-35-167-9
Interest Expense000031115
Unusual Expense
Non-Operating Income (Expense)3461-1-1000
Net Income Before Taxes-36-36-34-192-54-30-36-168-15
Income Taxes000-7-2-3-5-1-4
Consolidated Net Income-36-37-34-184-52-27-32-16761
Net Income From Continuing Operations-36-37-34-184-52-27-32-167-11
Net Income-36-37-34-184-52-27-32-16761
EPS (Recurring)-0.88-0.88-0.83-4.59-1.33-0.68-0.82-4.371.64
EPS (Basic, Before Extraordinaries)-0.88-0.88-0.83-4.59-1.33-0.68-0.82-4.371.64
EPS (Diluted)-0.88-0.88-0.83-4.59-1.33-0.68-0.82-4.371.64
EBITDA-35-362-61211-9-14316
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio11.46
Price To Sales Ratio1.991.511.430.831.092.423.021.471.94
Gross Margin54.3754.6954.1150.9951.3352.5353.9556.8243.45
Operating Margin-12.19-12.50-13.70-63.16-15.04-8.86-12.03-63.26-2.51
Net Margin-11.25-11.56-11.64-60.53-15.34-8.54-11.00-63.2616.99
Shares Outstanding424241403939383837
Market Capitalization638482418252369766879388695
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$16.21$14.00$11.80$9.59$7.38 Close Price0.00K86.00K172.00K258.00K344.01KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Nighan Warren JRSVP Quality and RegulatoryJul 30 '26Sale14.7223,370344,00664,745Jul 31
Nighan Warren JRSVP Quality and RegulatoryJul 22 '26Option Exercise0.0025,746089,786Jul 24
Trowbridge Stephen AEVP and CFOJul 22 '26Option Exercise0.0073,6770314,115Jul 24
Clemmer James CPresident and CEOJul 22 '26Option Exercise0.00236,7190889,176Jul 24
Campbell Chad ThomasSVP/GM, Vascular AccessJul 22 '26Option Exercise0.0029,2340111,006Jul 24
Piccinini LauraSVP InternationalJul 22 '26Option Exercise0.0036,383086,435Jul 24
Weiss Lawrence TSVP, Chief Legal OfficerOct 21 '25Buy11.8110,000118,10093,597Oct 22
Trowbridge Stephen AEVP and CFOOct 13 '25Buy11.168909,932256,629Oct 14
Clemmer James CPresident and CEOOct 09 '25Buy11.1510,000111,500882,529Oct 09
Nighan Warren JRSVP Quality and RegulatoryJan 16 '25Sale12.314,06049,97941,817Jan 17
Nighan Warren JRSVP Quality and RegulatoryOct 10 '24Buy6.0810060845,877Oct 10
Nighan Warren JRSVP Quality and RegulatoryOct 07 '24Buy6.097684,67745,777Oct 10
Trowbridge Stephen AEVP and CFOOct 08 '24Buy5.861,7009,962172,711Oct 08
Clemmer James CPresident and CEOOct 07 '24Buy6.0320,000120,600681,582Oct 08
Clemmer James CPresident and CEOJul 17 '24Option Exercise0.00108,6570690,312Aug 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.